British Journal of Cancer - Table of Contents alert Volume 106 Issue 1

TABLE OF CONTENTS Volume 106, Issue 1 (1-240) Published online 3 January 2012 In this issue Editorial Minireviews Clinical Studies Translational Therapeutics Molecular Diagnostics Epidemiology Letter to the Editor Also new today Advance online publication Advertisement 13th Milan Breast Cancer Conference We look forward to meeting you in Milan (Italy) from 22nd to 24th June 2011. For more information please visit the website www.breastmilan.com Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement British Journal of Cancer presents: Web Focus on Angiogenesis Angiogenesis is important for tumour growth and metastasis and is a key target for therapy. Greater understanding of the biology of angiogenesis has highlighted new targets for therapy and key interactions with VEGF, providing new avenues for improving the therapeutic performance of anti-VEGF therapies. This collection brings together a selection of key articles recently published in BJC. Read the articles for FREE   Editorial Top Personalised cancer follow-up: risk stratification, needs assessment or both? E K Watson, P W Rose, R D Neal, N Hulbert-Williams, P Donnelly, G Hubbard, J Elliott, C Campbell, D Weller and C Wilkinson Br J Cancer 2012 106: 1-5; 10.1038/bjc.2011.535 Full Text Minireviews Top Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer R Y Tsang and R S Finn Br J Cancer 2012 106: 6-13; 10.1038/bjc.2011.516 Abstract | Full Text Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care? J E Davies, S Neidle and D G Taylor Br J Cancer 2012 106: 14-17; 10.1038/bjc.2011.544 Abstract | Full Text Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets D C Gilbert, A J Chalmers and S F El-Khamisy Br J Cancer 2012 106: 18-24; advance online publication, November 22, 2011; 10.1038/bjc.2011.498 Abstract | Full Text Clinical Studies Top Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases R Bartsch, A Berghoff, U Pluschnig, Z Bago-Horvath, P Dubsky, A Rottenfusser, C DeVries, M Rudas, F Fitzal, K Dieckmann, R M Mader, M Gnant, C C Zielinski and G G Steger Br J Cancer 2012 106: 25-31; advance online publication, November 29, 2011; 10.1038/bjc.2011.531 Abstract | Full Text Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network Do the results of international clinical trials translate into a similar benefit for patients in South East Wales? R M Webster, J Abraham, N Palaniappan, A Caley, B Jasani and P Barrett-Lee Br J Cancer 2012 106: 32-38; advance online publication, November 22, 2011; 10.1038/bjc.2011.506 Abstract | Full Text Contribution of pelvic and para-aortic lymphadenectomy with sentinel node biopsy in patients with IB2–IIB cervical cancer E Chéreau, J-G Feron, M Ballester, C Coutant, C Bezu, R Rouzier, E Touboul and E Daraï Br J Cancer 2012 106: 39-44; advance online publication, December 6, 2011; 10.1038/bjc.2011.541 Abstract | Full Text Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial A Castañon, A Tristram, D Mesher, N Powell, H Beer, S Ashman, G Rieck, H Fielder, A Fiander and P Sasieni Br J Cancer 2012 106: 45-52; advance online publication, November 10, 2011; 10.1038/bjc.2011.496 Abstract | Full Text Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis H Hur, N K Kim, H G Kim, B S Min, K Y Lee, S J Shin, J H Cheon and S H Choi Br J Cancer 2012 106: 53-60; advance online publication, November 8, 2011; 10.1038/bjc.2011.469 Abstract | Full Text The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer D Goldstein, N Spry, M M Cummins, C Brown, G A van Hazel, S Carroll, S Selva-Nayagam, M Borg, S P Ackland, C Wratten, J Shapiro, I W T Porter, G Hruby, L Horvath, S Bydder, C Underhill, J Harvey and V J Gebski on behalf of the Australasian Gastro-Intestinal Trials Group Br J Cancer 2012 106: 61-69; advance online publication, December 1, 2011; 10.1038/bjc.2011.526 Abstract | Full Text Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer S McMeekin, R Patel, C Verschraegen, P Celano, J Burke, II, S Plaxe, P Ghatage, M Giurescu, C Stredder, Y Wang and T Schmelter Br J Cancer 2012 106: 70-76; advance online publication, November 22, 2011; 10.1038/bjc.2011.499 Abstract | Full Text Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours R Pili, B Salumbides, M Zhao, S Altiok, D Qian, J Zwiebel, M A Carducci and M A Rudek Br J Cancer 2012 106: 77-84; advance online publication, December 1, 2011; 10.1038/bjc.2011.527 Abstract | Full Text Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma A P Algazi, J S Weber, S C Andrews, P Urbas, P N Munster, R C DeConti, J Hwang, V K Sondak, J L Messina, T McCalmont and A I Daud Br J Cancer 2012 106: 85-91; advance online publication, November 29, 2011; 10.1038/bjc.2011.514 Abstract | Full Text Translational Therapeutics Top Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles S J Win, D G G McMillan, F Errington-Mais, V K Ward, S L Young, M A Baird and A A Melcher Br J Cancer 2012 106: 92-98; advance online publication, December 1, 2011; 10.1038/bjc.2011.538 Abstract | Full Text Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress K Ketola, M Hilvo, T Hyötyläinen, A Vuoristo, A-L Ruskeepää, M Orešič, O Kallioniemi and K Iljin Br J Cancer 2012 106: 99-106; 10.1038/bjc.2011.530 Abstract | Full Text Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma R B Erlich, Z Kherrouche, D Rickwood, L Endo-Munoz, S Cameron, A Dahler, M Hazar-Rethinam, L M de Long, K Wooley, A Guminski and N A Saunders Br J Cancer 2012 106: 107-115; advance online publication, November 24, 2011; 10.1038/bjc.2011.495 Abstract | Full Text Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide J Chang, D S Varghese, M C Gillam, M Peyton, B Modi, R L Schiltz, L Girard and E D Martinez Br J Cancer 2012 106: 116-125; advance online publication, December 8, 2011; 10.1038/bjc.2011.532 Abstract | Full Text Molecular Diagnostics Top Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis S Tsuji, Y Midorikawa, T Takahashi, K Yagi, T Takayama, K Yoshida, Y Sugiyama and H Aburatani Br J Cancer 2012 106: 126-132; advance online publication, November 17, 2011; 10.1038/bjc.2011.505 Abstract | Full Text Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer E C M Zeestraten, M Maak, M Shibayama, T Schuster, U Nitsche, T Matsushima, S Nakayama, K Gohda, H Friess, C J H van de Velde, H Ishihara, R Rosenberg, P J K Kuppen and K-P Janssen Br J Cancer 2012 106: 133-140; advance online publication, November 22, 2011; 10.1038/bjc.2011.504 Abstract | Full Text Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer L Ferdinande, C Decaestecker, L Verset, A Mathieu, X Moles Lopez, A-M Negulescu, T Van Maerken, I Salmon, C A Cuvelier and P Demetter Br J Cancer 2012 106: 141-147; advance online publication, November 22, 2011; 10.1038/bjc.2011.513 Abstract | Full Text A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT J L Bryant, J Britson, J M Balko, M Willian, R Timmons, A Frolov and E P Black Br J Cancer 2012 106: 148-156; advance online publication, November 1, 2011; 10.1038/bjc.2011.465 Abstract | Full Text Identification of markers of prostate cancer progression using candidate gene expression S E T Larkin, S Holmes, I A Cree, T Walker, V Basketter, B Bickers, S Harris, S D Garbis, P A Townsend and C Aukim-Hastie Br J Cancer 2012 106: 157-165; advance online publication, November 10, 2011; 10.1038/bjc.2011.490 Abstract | Full Text Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression B Scaggiante, B Dapas, S Bonin, M Grassi, C Zennaro, R Farra, L Cristiano, S Siracusano, F Zanconati, C Giansante and G Grassi Br J Cancer 2012 106: 166-173; advance online publication, November 17, 2011; 10.1038/bjc.2011.500 Abstract | Full Text Investigating prostate cancer tumour–stroma interactions: clinical and biological insights from an evolutionary game D Basanta, J G Scott, M N Fishman, G Ayala, S W Hayward and A R A Anderson Br J Cancer 2012 106: 174-181; advance online publication, December 1, 2011; 10.1038/bjc.2011.517 Abstract | Full Text Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma J Kurashige, M Watanabe, M Iwatsuki, K Kinoshita, S Saito, Y Hiyoshi, H Kamohara, Y Baba, K Mimori and H Baba Br J Cancer 2012 106: 182-188; advance online publication, November 22, 2011; 10.1038/bjc.2011.509 Abstract | Full Text Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients G Goebel, R Berger, A M Strasak, D Egle, E Müller-Holzner, S Schmidt, J Rainer, E Presul, W Parson, S Lang, A Jones, M Widschwendter and H Fiegl Br J Cancer 2012 106: 189-198; advance online publication, November 22, 2011; 10.1038/bjc.2011.510 Abstract | Full Text Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population K H Allin, S E Bojesen, J S Johansen and B G Nordestgaard Br J Cancer 2012 106: 199-205; advance online publication, November 17, 2011; 10.1038/bjc.2011.501 Abstract | Full Text Epidemiology Top Correlates of anti-EBV EBNA1 IgA positivity among unaffected relatives from nasopharyngeal carcinoma multiplex families C M Chang, K J Yu, W L Hsu, J M Major, J Y Chen, P J Lou, M Y Liu, S R Diehl, A M Goldstein, C J Chen and A Hildesheim Br J Cancer 2012 106: 206-209; advance online publication, November 17, 2011; 10.1038/bjc.2011.502 Abstract | Full Text Reproductive factors and risk of oesophageal and gastric cancer in the Million Women Study cohort J Green, A Roddam, K Pirie, O Kirichek, G Reeves and V Beral for the Million Women Study collaborators Br J Cancer 2012 106: 210-216; advance online publication, November 29, 2011; 10.1038/bjc.2011.525 Abstract | Full Text Risk of prostate cancer in a population-based cohort of men with coeliac disease J F Ludvigsson, K Fall and S Montgomery Br J Cancer 2012 106: 217-221; advance online publication, December 1, 2011; 10.1038/bjc.2011.536 Abstract | Full Text Urinary human polyomavirus and papillomavirus infection and bladder cancer risk J Polesel, T Gheit, R Talamini, N Shahzad, O Lenardon, B Sylla, C La Vecchia, D Serraino, M Tommasino and S Franceschi Br J Cancer 2012 106: 222-226; advance online publication, November 24, 2011; 10.1038/bjc.2011.519 Abstract | Full Text A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women G C Kabat, M Y Kim, H D Strickler, J M Shikany, D Lane, J Luo, Y Ning, M J Gunter and T E Rohan Br J Cancer 2012 106: 227-232; advance online publication, November 29, 2011; 10.1038/bjc.2011.512 Abstract | Full Text Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case–control study M C Bradley, L J Murray, M M Cantwell and C M Hughes Br J Cancer 2012 106: 233-239; advance online publication, November 22, 2011; 10.1038/bjc.2011.511 Abstract | Full Text Letter to the Editor Top Aspirin as adjuvant therapy in childhood cancer? G Morgan Br J Cancer 2012 106: 240; advance online publication, November 10, 2011; 10.1038/bjc.2011.467 Full Text Advertisement Ensure your access to British Journal of Cancer If you are unable to access the articles in this Table of Contents e-alert, your library may not subscribe to this journal. Our online recommendation form is a simple way to make your librarian aware that this journal is valuable to your research. Recommend now at http://www.nature.com/librec/svc/request/makeCommRequest?id=2.   Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.